VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer.

Authors: Ruben Raychaudhuri, Roman Gulati, Erolcan Sayar, Andrii Hannochka, Hiba M. Khan, Heather H. Cheng, Andrew Caleb Hsieh, Jessica E. Hawley, Petros Grivas, Rajitha Sunkara, Rosa Nadal, Todd Yezefski, Evan Y. Yu, Robert Bruce Montgomery, Joshua Michael Lang, Delphine L. Chen, Peter Nelson, Amir Iravani, Michael C. Haffner, Michael Thomas Schweizer

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5112

Source: Full article

---

Abstract

TPS5112